FDA panel OKs Tresiba but raises red flag on heart safety
November 12 2012
A risk signal also encouraged the panel to vote 12-0 in favor of a cardiovascular outcomes study.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.